Drug Trial Radar · NCT04003142
A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause - 2
Last checked: Nov 20, 2026Latest source record: Nov 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
501
Actual
Start
Jul 10, 2019
Primary completion
Jul 30, 2020
Study completion Apr 23, 2021
Sponsor
- Lead sponsor
- Astellas Pharma Global Development, Inc.Astellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Jul 1, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 40 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study was for women in menopause with moderate to severe hot flashes. Menopause, a normal part of aging, is the time of a woman's last period. Hot flashes can interrupt a woman's daily life. The study treatments are fezolinetant 30 mg (1 tablet of fezolinetant and 1 placebo tablet) once a day, fezolinetant 45 mg (2 tablets of fezolinetant) once a day or placebo (2 tablets) once a day. (Placebo is a dummy treatment that looks like medicine but does not have any medicine in it.) The study compared fezolinetant and placebo after 4 and 12 weeks of dosing. The study evaluated if fezolinetant reduces the number of hot flashes and the study evaluated if fezolinetant reduces the severity of the hot flashes. Women in the study received an electronic handheld device at the first study visit. (It is similar to a smart phone.) Each day of the study, study participants used this to record their hot flashes. Their record for the 10 days before the start of study treatment was checked. They remained in the study if their record shows 7 or 8 moderate to severe hot flashes per day (50 or more per week). Next, they were picked for 1 of the 2 study treatments (fezolinetant or placebo) by chance alone. It is like flipping a coin. The study participants took study treatment for 52 weeks. The first 12 weeks of study treatment was "double-blinded." That means that the study participants and the study doctors did not know who took which of the study treatments (fezolinetant 30 mg, fezolinetant 45 mg or placebo) during that time. The last 40 weeks of study treatment was "noncontrolled." That means that each study participant and the study doctors knew which study treatment that study participant took during that time. Women who took fezolinetant during the first 12 weeks continued to take the same dose. Women who took placebo during the first 12 weeks took fezolinetant. Their dose was either 30 mg or 45 mg fezolinetant. At weeks 2, 4, 8, 12, 14, 16 and then once a month, the study participants went to the hospital or clinic for a check-up. They were asked about medications, side effects and how they felt. Other checks included physical exam and vital signs (heart rate, temperature and blood pressure). Blood and urine was collected for laboratory tests. Study participants completed questionnaires that were about how hot flashes affect their daily life. Study participants who had their uterus had the following 2 tests done at the first and last study visits. One of the 2 tests was endometrial biopsy. This test involved removing a small amount of tissue from the inside lining of the uterus. The tissue was then checked under a microscope. The other test was transvaginal ultrasound. This test used sound waves to create pictures of the organs in the pelvis. The sound waves are transmitted by a probe (transducer), which was placed inside the vagina. Study participants might have a screening mammogram done at the first and/or last study visit. A mammogram is an x-ray picture of the breasts used to screen for breast cancer. Study participants who did not have this test done in the last 12 months had it done at the first study visit. They had done at the last study visit if they were due for their screening mammogram and their own doctor agrees. The last check-up at the hospital or clinic was 3 weeks after the last dose of study treatment.
Conditions
- Hot Flashes
Interventions
FezolinetantDrug
Oral tablet
placeboDrug
Oral Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in The Mean Frequency of Moderate to Severe VMS at Week 4Time frame: Baseline and week 4
- Change From Baseline in The Mean Frequency of Moderate to Severe VMS at Week 12Time frame: Baseline and week 12
- Change From Baseline in The Mean Severity of Moderate to Severe VMS at Week 4Time frame: Baseline and week 4
- Change From Baseline in The Mean Severity of Moderate to Severe VMS at Week 12Time frame: Baseline and week 12
Locations
93 sites in 7 countries. Site status is shown where the registry gives one.
Mesa Obstetricians and Gynecologists
Mesa, Arizona
Precision Trials
Phoenix, Arizona
Visions Clinical Research - Tuscon
Tucson, Arizona
Excell Research
Oceanside, California
Dream Team Clinical Research, LLC
Pomona, California
Clinical Trials Research
Sacramento, California
Wake Research Associates, LLC
San Diego, California
Women's Healthcare Affiliates
San Diego, California
Bayview Research Group
Valley Village, California
Downtown Women's Health Care
Denver, Colorado
Horizons Clincial Research Center LLC
Denver, Colorado
Physicians' Research Options/Red Rocks OB/GYN
Lakewood, Colorado
Helix Biomedics
Boynton Beach, Florida
Renaissance Research and Medical Group, Inc.
Cape Coral, Florida
Nature Coast Clinical Research
Crystal River, Florida
Bioclinica Research, Melbourne
Melbourne, Florida
LCC Medical Research Institute, LLC
Miami, Florida
Suncoast Clinical Research, Inc.
Miami, Florida
Suncoast Research
Miami, Florida
Medical Health Center & Research
Miami, Florida
Healthcare Clinical Data Inc
North Miami, Florida
Sensible Healthcare LLC
Ocoee, Florida
Bioclinica Research
Orlando, Florida
Ormond Medical Arts Pharmaceutical Research Center
Ormond Beach, Florida
Progressive Medical Research
Port Orange, Florida
Physician Care Clinical Research, LLC
Sarasota, Florida
Meridien Research
St. Petersburg, Florida
GCP Clinical Research, LLC
Tampa, Florida
Comprehensive Clinical Development
West Palm Beach, Florida
Clinical Research of Central Florida
Winter Haven, Florida
Georgia Research for Women
Atlanta, Georgia
Agile Clinical Research Trials, LLC
Atlanta, Georgia
iResearch Atlanta LLC
Decatur, Georgia
WR-Mount Vernon Clinical Research
Sandy Springs, Georgia
Georgia Clinical Research
Snellville, Georgia
Elite Clinical Trials
Blackfoot, Idaho
ASR, LLC-Advanced Specialty Research
Nampa, Idaho
Affinity Clinical Research Institute
Oak Brook, Illinois
Cypress Medical Research Center
Wichita, Kansas
Praetorian Pharmaceutical Research
Marrero, Louisiana
Showing 40 of 93 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.